PEMBROLIZUMAB IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PATIENTS WITH EGFR MUTATION AND ALK POSITIVE NSCLC (NON-SMALL CELL LUNG CANCER) WITH PROGRESSIVE DISEASE FOLLOWING PRIOR TYROSINE KINASE INHIBITORS (TKIS):